A coalition of major pharmaceutical companies and industry trade groups filed a lawsuit against the Trump administration seeking to block new Medicare drug price negotiation policies set to take effect next year. Pharmaceutical stocks tumbled immediately, with the Dow Jones Industrial Average falling 0.7 percent to $51,180 and the S&P 500 sliding 0.2 percent to $7,802.
The policy empowers Medicare to negotiate prices for high-cost drugs without generic competition. Analysts estimate the program could cut pharmaceutical industry sales by up to $100 billion over the next decade, a material threat to established revenue models for major players.
The pharmaceutical lobby argues the program violates constitutional protections under the Fifth Amendment's takings clause, contending it amounts to government price-setting rather than negotiation. They claim the policy will stifle innovation and research investment.
Eli Lilly and Johnson & Johnson hold substantial market share in Medicare Part D, making them particularly vulnerable to price adjustments under the new framework. Goldman Sachs maintained a "Neutral" rating on the sector, citing regulatory uncertainty as a persistent headwind.
The lawsuit was filed in U.S. District Court for the District of Columbia. The Trump administration has 30 days to file its formal response. A preliminary injunction hearing could occur as early as late November, the next critical event determining whether the policies are temporarily halted before implementation.
